首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1619158

乳癌市場規模、佔有率、成長分析、按癌症類型、按治療方法、按最終用戶、按地區 - 行業預測，2024-2031 年

Breast Cancer Market Size, Share, Growth Analysis, By Type (Invasive Ductal Carcinoma, Invasive Lobular Carcinoma), By Cancer Type (Hormone Receptor, HER2+), By Treatment, By End User, By Region - Industry Forecast 2024-2031

出版日期: 2024年12月18日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球乳癌市場規模將為319億美元，預計將從2023年的352億美元成長到2031年的778億美元，預測期間（2024-2031年）複合年成長率為10.4%。

由於生活方式的改變、人口老化、遺傳因素、荷爾蒙失衡等導致全球發病率上升，乳癌市場正在強勁成長。越來越多的患者需要創新的治療方法和先進的診斷工具。分子影像、基因檢測和標靶治療技術進步正在改善早期檢測和治療結果，刺激了市場需求。此外，在強調早期檢測的政府宣傳活動的支持下，人們對乳癌的認知不斷提高，也刺激了人們對篩檢計畫的參與。然而，挑戰仍然存在，例如治療費用高昂，這構成了獲得治療的障礙，特別是對於低收入群體而言。乳癌具有多種亞型，其複雜性使治療個人化變得複雜，並凸顯了有效的分子分析和基因檢測以最佳化患者治療結果的必要性。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 西班牙
- 法國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東/非洲
- 海灣合作理事會國家
- 南非
- 其他中東/非洲

競爭資訊

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2023）
主要企業簡介
- 公司簡介
- 產品系列分析
- 按細分市場分類的佔有率分析
- 收益與前一年同期比較（2021-2023）

主要企業簡介

Pfizer Inc
Novartis Ag
F. Hoffmann-La Roche
AstraZeneca Plc
Glaxosmithkline
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries
Merck & Co
Bristol Myers Squiib
Kyowa Kirin
Eisai Co.Ltd
Sanofi
Eli Lilly and Company
Genentech, Inc.
Roche Holding AG
Johnson & Johnson
AbbVie Inc.
Daiichi Sankyo Company, Limited
Amgen Inc.
Celgene Corporation

結論和建議

簡介目錄

Product Code: SQMIG35D2186

Global Breast Cancer Market size was valued at USD 31.9 billion in 2022 and is poised to grow from USD 35.2 billion in 2023 to USD 77.8 billion by 2031, growing at a CAGR of 10.4% during the forecast period (2024-2031).

The breast cancer market is experiencing robust growth due to rising global incidence rates, driven by lifestyle changes, aging, genetic factors, and hormonal imbalances. This increasing patient population demands innovative therapies and advanced diagnostic tools. Technological advancements, such as molecular imaging, genetic testing, and targeted therapies, enhance early detection and treatment outcomes, fueling market demand. Furthermore, heightened awareness about breast cancer has spurred participation in screening programs, supported by government campaigns emphasizing early detection. However, challenges persist, including the high costs of treatments, which pose barriers to access, particularly in low-income areas. The complexity of breast cancer, with its various subtypes, complicates treatment personalization, underscoring the need for efficient molecular profiling and genetic testing to optimize patient outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Breast Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Breast Cancer Market Segmental Analysis

Global Breast Cancer Market is segmented by Type, Cancer Type, Treatment, End User and Region. Based on Type, the market is segmented into Invasive Ductal Carcinoma, Invasive Lobular Carcinoma, Others. Based on Cancer Type, the market is segmented into Hormone Receptor, HER2+. Based on Treatment, the market is segmented into Chemotherapy, Surgery & Radiation Therapy, Targeted Therapy, Biologic Therapy, Hormonal Therapy. Based on End User, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others. Based on Region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Breast Cancer Market

The Global Breast Cancer market is significantly influenced by the rising awareness surrounding the disease and the critical importance of early detection. Efforts to educate the public about breast cancer have driven more individuals to engage in regular screenings and health check-ups. Various government initiatives, awareness campaigns, and the work of advocacy organizations are pivotal in promoting the significance of early diagnosis, which in turn bolsters the growth of the market. This comprehensive approach not only boosts participation in screening programs but also enhances overall understanding, leading to better health outcomes and fostering further development within the breast cancer sector.

Restraints in the Global Breast Cancer Market

The global breast cancer market faces significant restraints due to challenges in personalized medicine. Breast cancer is a complex and heterogeneous disease characterized by various subtypes, each exhibiting distinct treatment responses. This variability complicates the development of personalized treatment strategies, making it difficult to determine the most effective therapies for individual patients. As a result, the implementation of precision medicine in breast cancer care can be both challenging and time-consuming. This complexity hinders the broader adoption of tailored therapeutic approaches, ultimately impacting the market's growth potential and the advancement of innovative treatment options for patients.

Market Trends of the Global Breast Cancer Market

The global breast cancer market is increasingly characterized by the rise of targeted therapies, which have transformed treatment paradigms through their precision-driven approach. HER2-targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors, have markedly enhanced survival rates in HER2-positive cases and set a precedent for optimizing patient outcomes. Furthermore, the development of novel therapies targeting additional molecular abnormalities, such as PI3K and CDK4/6 inhibitors, is expanding treatment options and showing promise across various breast cancer subtypes. This shift towards personalized medicine is expected to drive market growth and foster innovation in therapeutic strategies, reflecting a broader commitment to improving care standards in oncology.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Driver & Opportunities
- Restraints & Challenges
Porters Analysis & Impact
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index, 2023
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Technology Assessment
Regulatory Landscape
Customer & Buying Criteria Analysis
Pipeline Analysis
Disease Epidemiology
Patent Analysis

Global Breast Cancer Market Size by Type & CAGR (2024-2031)

Market Overview
Invasive Ductal Carcinoma
Invasive Lobular Carcinoma
Others

Global Breast Cancer Market Size by Cancer Type & CAGR (2024-2031)

Market Overview
Hormone Receptor
HER2+

Global Breast Cancer Market Size by Treatment & CAGR (2024-2031)

Market Overview
Chemotherapy
- Antimetabolites
- Anthracyclines
- Taxanes
- Alkylating Agents
Surgery & Radiation Therapy
Targeted Therapy
- Throsine Kinase Inhibitors
- Monoclonal Antibodies
Biologic Therapy
Hormonal Therapy
- Estrogen-Receptor Modulators
- Aromatese Inhibitors
- Others

Global Breast Cancer Market Size by End User & CAGR (2024-2031)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Global Breast Cancer Market Size & CAGR (2024-2031)

North America (Type, Cancer Type, Treatment, End User)
- US
- Canada
Europe (Type, Cancer Type, Treatment, End User)
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific (Type, Cancer Type, Treatment, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
Latin America (Type, Cancer Type, Treatment, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Cancer Type, Treatment, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2023
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

Pfizer Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis Ag
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca Plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Glaxosmithkline
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squiib
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kyowa Kirin
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co.Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genentech, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments